New analysis of data from the randomized, controlled, DIG trial has indicated that digoxin might help to reduce the risk of 30-day all-cause hospital admission in ambulatory, elderly patients with heart failure and reduced ejection fraction. The results were presented at the 2013 ACC Scientific Sessions. Notably, the DIG trial was conducted at a time (the early 1990s) when β-blockers were not yet approved for use in patients with heart failure. The investigators of the new analysis of DIG suggest that future studies should examine the effect of digoxin on 30-day readmission rates.